Leqembi Starts to Deliver for Eisai and Biogen

Why It Matters

Leqembi’s accelerating uptake improves Biogen’s revenue mix and signals broader acceptance of subcutaneous Alzheimer’s therapies, potentially reshaping the market’s treatment paradigm.

Key Takeaways

• Leqembi Q4 sales rose 54% to $134M.
• US contributed $78M of Leqembi revenue.
• Subcutaneous version approved, may boost adoption.
• FDA decision on injectable induction due May 2026.

Pulse Analysis

The Alzheimer’s therapeutics landscape has long been dominated by intravenous infusions, limiting patient convenience and clinic capacity. Leqembi’s recent FDA clearance for a once‑weekly subcutaneous formulation reduces the need for infusion‑center visits, aligning the drug with a growing preference for at‑home administration. This shift not only broadens the eligible patient pool but also positions Leqembi competitively against other anti‑amyloid agents that remain infusion‑only, potentially accelerating market penetration as payors and providers favor lower operational costs.

From a financial perspective, the surge in Leqembi sales provides a crucial counterbalance to Biogen’s weakening multiple‑sclerosis and spinal muscular atrophy segments. While overall fourth‑quarter revenue slipped 7%, the combined contribution of Leqembi, Skyclarys, Zurzuvae and Qalsody approached $1 billion, underscoring the company’s diversification strategy. The strong performance of these niche‑indication drugs illustrates Biogen’s ability to leverage its R&D pipeline to offset declines in legacy franchises, a pattern increasingly common among large biotech firms seeking sustainable growth.

Looking ahead, the pending FDA decision on extending the subcutaneous formulation to the induction phase could further unlock Leqembi’s market potential. Approval would eliminate the 18‑month intravenous lead‑in, simplifying the treatment journey and likely driving higher adoption rates. Moreover, the success of Leqembi’s delivery innovation may encourage other developers to pursue similar administration routes, influencing industry standards and shaping future investment priorities in neuro‑degenerative therapeutics. The outcome will be a key barometer for how quickly the Alzheimer’s market can transition toward more patient‑centric delivery models.